American Heart Journal
Volume 159, Issue 3 , Pages 428-433 , March 2010

Propranolol and the risk of hospitalized myopathy: Translating chemical genomics findings into population-level hypotheses

  • Soko Setoguchi, MD, DrPH

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Boston, MA
    • Corresponding Author InformationReprint requests: Soko Setoguchi, MD, DrPH, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont St, Suite 3030, Boston, MA 02130.
    • Cofirst authors.
    • ,
  • John M. Higgins, MD

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
    • Cofirst authors.
    • Current address: Center for Systems Biology and Department of Pathology, Massachusetts General Hospital, and Department of Systems Biology, Harvard Medical School.
    • ,
  • Helen Mogun, MS

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Boston, MA
    • ,
  • Vamsi K. Mootha, MD

      Affiliations

    • Center for Human Genetic Research, Massachusetts General Hospital, Broad Institute of MIT and Harvard, and Department of Systems Biology, Harvard Medical School, Boston, MA
    • ,
  • Jerry Avorn, MD

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Boston, MA

Received 9 June 2009 ,Accepted 2 December 2009.

References 

  1. Wagner BK, Kitami T, Gilbert TJ, et al. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol. 2008;26:343–351
  2. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291:C1208–C1212
  3. Cheong HI, Johnson J, Cormier M, et al. In vitro cytotoxicity of eight beta-blockers in human corneal epithelial and retinal pigment epithelial cell lines: comparison with epidermal keratinocytes and dermal fibroblasts. Toxicol In Vitro. 2008;22:1070–1076
  4. Stergachis AS. Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharm. 1988;22:157–161
  5. McKenzie DA, Semradek J, McFarland BH, et al. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol. 2000;53:1248–1257
  6. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920
  7. Glynn RJ, Schneeweiss S, Wang PS, et al. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59:819–828
  8. Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol. 2005;58:171–174
  9. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–763
  10. Blessing W, Walsh JC. Myotonia precipitated by propranolol therapy. Lancet. 1977;1:73–74
  11. Forfar JC, Brown GJ, Cull RE. Proximal myopathy during beta-blockade. Br Med J. 1979;2:1331–1332
  12. Sobie EA, Guatimosim S, Song LS, et al. The challenge of molecular medicine: complexity versus Occam's razor. J Clin Invest. 2003;111:801–803

PII: S0002-8703(09)00962-4

doi: 10.1016/j.ahj.2009.12.008

American Heart Journal
Volume 159, Issue 3 , Pages 428-433 , March 2010

Article Tools